Djatche, Laurence M.
Varga, Stefan
Lieberthal, Robert D.
Article History
First Online: 24 April 2018
Compliance with Ethical Standards
: This work was previously presented at the 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting in Boston, MA. The abstract was published in the journal Value in Health [CitationRef removed].
: No funding was received for this study.
: Dr. Varga and Dr. Djatche’s efforts were supported by a fellowship funded by Novartis, and both were employees at Jefferson at the time the study was done. Dr. Lieberthal reports previously receiving funding from Novartis as a mentor for the university fellows program and research funding from New Haven Pharmaceuticals. All such funds were paid to Thomas Jefferson University. He also has received consulting fees from Shire Pharmaceuticals for consulting unrelated to aspirin therapy or cardiovascular disease.